“…It appears to be well absorbed and exhibits biphasic decline in both blood and plasma concentrations, with a relatively long elimination half-life of 49.8 h. JPC-2997's elimination half-life is longer than those of dihydroartemisinin (25 min) (23), amodiaquine (ϳ7 h) (24), atovaquone (12 h) (25), and mefloquine (17 h) (26), and comparable to that of chloroquine (47 h) (27) but shorter than that of piperaquine (15 days) (28). Unlike the quinoline antimalarials amodiaquine (29), chloroquine (30), and pyronaridine (31), which concentrate in erythrocytes, JPC-2997 does not appear to accumulate in erythrocytes, with a blood-to-plasma concentration ratio of 0.7. However, accurately measuring JPC-2997's uptake into erythrocytes requires not only measurement of the blood-to-plasma concentration ratio but also knowledge of the unbound fraction of JPC-2997 in plasma, which is presently unknown, and the hematocrit of the blood sample.…”